Beyondspring Inc. priced its IPO of 174,286 shares at $20 each and sold about 2.5 million shares at the same price in a private placement, hauling down about $54.3 million, which "probably for some companies is not that much," CEO Lan Huang told BioWorld Today. "But it can really help us to run our current defined clinical programs," since the New York-headquartered company bases its clinical operations in China. Shares (NASDAQ:BYSI) closed Thursday at $16.80, down 16 percent.